# Mezomax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mezomax

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.mezomaxinc.com
- Latest round: Seed (Dec 11, 2017)
- Investors on record: 2

## About

Mezomax is a technology company focused on delivering innovative software solutions designed to enhance operational efficiency for businesses across various sectors, particularly within the digital transformation landscape.Mezomax specializes in providing advanced software solutions that address specific operational needs. The company was co-founded by Dmitriy Rybin and Kirill Susloparov, with Kirill serving as the CEO. It is headquartered in San Francisco, US. The company successfully raised seed funding in December 2017 from investors SOSV and IndieBio, marking a significant step in its growth trajectory. Mezomax has completed one investment deal to date.Mezomax offers a range of innovative products targeting operational efficiency through advanced software solutions. These solutions are tailored to streamline processes, improve data management, and facilitate better decision-making. The company's products, launched in recent years, cater to small and medium-sized enterprises as well as large corporations, focusing on the North American and European markets.Mezomax generates revenue primarily through subscription-based models, allowing clients to access its flagship software products. Clients can choose from various service packages with tiered pricing based on usage and features, offering flexibility for different organizational sizes. This structured pricing approach supports long-term partnerships and ensures a steady revenue stream for ongoing product development and customer support.Looking ahead, Mezomax plans to expand its product offerings, with new software solutions currently in development expected to launch in the upcoming year. The company is also targeting expansion into additional geographic markets, specifically in Asia and South America, aiming for entry by mid-2024. The funds raised in December 2017 are intended to support these growth initiatives, facilitating product development and market entry strategies.

## Funding rounds

- Seed, Dec 11, 2017 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed